{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000075","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.657064+00:00","generated_at":"2026-05-30T03:30:49.995366+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Akebia Q3 2024 net loss $20M; Vafseo launch on track for Jan 2025 with 60% dialysis patient coverage","bullets":["Total revenues $37.4M in Q3 2024 vs $42.0M in Q3 2023, driven by Auryxia volume decline.","Net loss $20.0M in Q3 2024 vs $14.5M in Q3 2023, including $4.4M non-cash interest from Vifor settlement.","Cash and equivalents $34.0M as of Sep 30, 2024; company expects funding to cover operations including Vafseo launch for at least two years.","Vafseo commercial supply contracts cover over 300,000 patients (~60% of US dialysis patients); TDAPA reimbursement starts Jan 1, 2025.","U.S. market availability for Vafseo expected in January 2025; VOICE trial initiated with US Renal Care."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000075","json":"https://secwatch.observer/filing/0001517022-24-000075.json","markdown":"https://secwatch.observer/filing/0001517022-24-000075.md","text":"https://secwatch.observer/filing/0001517022-24-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000075/0001517022-24-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000075/akba-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:30:49.995366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}